Stocktoria
ALNYLAM PHARMACEUTICALS, INC. ALNY
ALNYLAM PHARMACEUTICALS, INC. (ALNY) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $3.7B at a 8.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -1.91 — grey zone (between the usual thresholds). A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-04 | Truist Securities | Buy (main) |
| 2026-08-04 | HC Wainwright & Co. | Buy (main) |
| 2026-08-03 | Raymond James | Strong Buy (up) |
| 2026-08-03 | Citigroup | Buy (main) |
| 2026-08-03 | Barclays | Overweight (main) |
| 2026-07-31 | JP Morgan | Overweight (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.52 |
| Retained earnings / assets | -1.35 |
| EBIT / assets | 0.101 |
| Equity / liabilities | 0.189 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | 5/9 | -0.11 | 124 | +65.2% |
| BMRN | BIOMARIN PHARMACEUTICAL INC | 4/9 | 7.43 | 32.7 | +12.9% |
| UTHR | UNITED THERAPEUTICS Corp | 7/9 | 16.93 | 17.4 | +10.6% |
| PRGO | PERRIGO Co plc | 4/9 | -0.37 | — | -2.8% |
| JAZZ | Jazz Pharmaceuticals plc | 5/9 | 1.63 | — | +4.9% |
| AMRX | Amneal Pharmaceuticals, Inc. | 7/9 | 2.06 | 76.3 | +8% |
| ELAN | Elanco Animal Health Inc | 6/9 | — | — | +6.2% |
About ALNYLAM PHARMACEUTICALS, INC.
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
FAQ
Is ALNY financially healthy?
ALNYLAM PHARMACEUTICALS, INC.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does ALNY pay a dividend?
No, ALNYLAM PHARMACEUTICALS, INC. does not currently pay a dividend.
How profitable is ALNY?
In FY2025, ALNYLAM PHARMACEUTICALS, INC. had a net margin of 8.4% and a return on equity of 39.8%.
What is ALNY's P/E ratio?
ALNYLAM PHARMACEUTICALS, INC.'s trailing price-to-earnings (P/E) ratio is about 124.0×, based on its latest annual earnings.
What is the analyst price target for ALNY?
The average Wall-Street price target for ALNYLAM PHARMACEUTICALS, INC. is $375.76, about 67.8% above the recent price, from 24 analysts (consensus: buy).
Is ALNY a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ALNYLAM PHARMACEUTICALS, INC.: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone, a P/E of about 124.0×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.